Trump tariff pressure: AstraZeneca to move production to US, announces $50 billion manufacturing push
AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment. This move aligns with the company’s expectation that 50% of its revenue will come from the U.S. by 2030. The decision comes amid rising tariff pressures from the Trump administration, aiming to bolster domestic drug supply chains.🕒 1 min read
AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment. This move aligns with the company’s expectation that 50% of its revenue will come from the U.S. by 2030. The decision comes amid rising tariff pressures from the Trump administration, aiming to bolster domestic drug supply chains.
Continue Reading
- Duleep Trophy final: Ankit, Siddarth delay Central Zone’s victory march
- Monsoon, El Niño and market trends: NSE highlights key risks for India’s 2026 economy
- Ganja Worth Rs 1 Crore, Some Exotic Animals Seized At Bengaluru Airport
- CUET UG 2025 Provisional Answer Key Out, Challenge Window Open Till June 20
- 24 Women Arrested With Gold Worth Rs 37 Crore At Mumbai Airport
-
Virat Kohli Ends Long Silence On Decision To Quit Test Captaincy: “Became Focal Point”
-
“Getting Back To Normalcy”: Delhi Airport Issues Advisory Amid IndiGo Chaos
- Fire Sweeps Through Market In Kerala, Dozens Of Establishments Destroyed
- Abhishek Sharma Scripts T20I History In Asia Cup Opener, Becomes First Player In The World To…
- Asia Cup 2025: Complete squads of all teams, fixtures
